ASHPOfficial

ASHP’s education director, Hannah Post, is joined by Curtis Geier, emergency medicine clinical pharmacist at San Francisco General Hospital, as he discusses his upcoming Midyear sessions that focus on the role of pharmacists in the care of patients in cardiac arrest.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Pharmacists providing rapid sequence intubation (RSI) care are faced with evolving standards of care in special patient populations. This episode features RSI pharmacology in special patient populations, including myasthenia gravis, pregnancy and obesity. CE for this episode expires on October 18, 2027. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Collaborative practice agreements (CPAs) are formal agreements between pharmacists and other healthcare providers that allow pharmacists to perform specific tasks independently at the top of their license. CPAs are a powerful tool widely used in the outpatient setting but not used as frequently in the inpatient setting. This episode discusses the considerations for developing and implementing a successful inpatient CPA and the benefits to patient care quality, safety, and efficiency.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this podcast, Dr. Dusty Linn discusses the AJHP Clinical Consultation "Strategies to prevent awareness with paralysis following administration of neuromuscular blocking agents” with host and AJHP Editor in Chief Dr. Daniel Cobaugh.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP’s senior education director Cindy Von Heeringen is joined by Lisa Janssen Carlson, IDS manager, and Craig Michael, data science pharmacist, both from the University of California, San Francisco as they discuss their upcoming Midyear session that focuses on incorporating AI in current pharmacy practice settings to enhance or streamline workflows.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Members of the Council on Therapeutics unpack two ASHP policies adopted in the 2025 House of Delegates— one addressing the FDA’s proposal to change drug naming conventions, and the other requiring height and weight on certain medication orders. They share why these policies matter, the challenges encountered during the policy process, and the improvements they hope to see in patient care as a result.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This session focuses on various pharmacogenomics implementation models in oncology. Presenters discuss how pharmacogenomics was implemented at their respective institution, how each addressed unique barriers to implementation, and considerations for scalability, sustainability, and expansion of pharmacogenomics testing in oncology over the next 5+ years. CE for this episode expires two years after publication.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, the team from The Ohio State University Wexner Medical Center discusses their award-winning ASHP Best Practices submission.  They share how the program leveraged the unique expertise of pharmacist informaticists to take advantage of  EHR and build tools to automate the selection of preferred biosimilar, iron and Biosimilars, Iron, and 505(b)(2)  products based on the patient's insurance and hospital formulary preferences and time to payor approval for patients, reduced the administrative burden of the PA process, and improved the quality of our patient care.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP’s education director, Hannah Post is joined by Angela Cassano, president of Pharmfusion Consulting, LLC, William Hammonds, clinical pharmacy manager at West Virginia University Medicine, and Carrington Huneycutt, director of clinical pharmacy at Tandem Health, South Carolina, as they discuss their upcoming Midyear session that focuses on implementation and evolution of clinical pharmacy technician roles. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Pharmacists providing care to patients following toxicologic ingestions of medications and other substances are often relied upon for treatment and monitoring recommendations. Many pharmacists do not routinely care for patients following toxicologic ingestions of medications or other substances and are unfamiliar with clinical presentation of various toxidromes and ultimately management strategies. This episode covers anticholinergic, cholinergic, sedative-hypnotic, opioid, sympathomimetic, serotonin syndrome, neuroleptic malignant syndrome, and malignant hypethermia toxidromes and discusses the clinical presentation and causative medications/substances and general treatment approaches, with an emphasis on antidotes for specific toxidromes including physostigmine, naloxone, flumazenil, atropine, and pralidoxime. CE expires two years from when this episode was originally published.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.